Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| natural killer cell | 20 studies | 27% ± 8% | |
| CD16-positive, CD56-dim natural killer cell, human | 14 studies | 31% ± 9% | |
| mature NK T cell | 12 studies | 28% ± 9% | |
| CD8-positive, alpha-beta T cell | 7 studies | 25% ± 8% | |
| gamma-delta T cell | 6 studies | 23% ± 7% | |
| effector memory CD8-positive, alpha-beta T cell, terminally differentiated | 5 studies | 26% ± 6% | |
| effector memory CD8-positive, alpha-beta T cell | 5 studies | 23% ± 6% |
Insufficient scRNA-seq data for expression of FCRL6 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| lung | 99% | 200.82 | 575 / 578 | 62% | 2.02 | 712 / 1155 |
| kidney | 90% | 56.84 | 80 / 89 | 66% | 2.40 | 598 / 901 |
| breast | 98% | 73.86 | 449 / 459 | 52% | 1.47 | 578 / 1118 |
| thymus | 90% | 57.75 | 589 / 653 | 47% | 1.25 | 284 / 605 |
| uterus | 91% | 47.79 | 155 / 170 | 31% | 0.82 | 142 / 459 |
| prostate | 92% | 54.92 | 226 / 245 | 22% | 0.41 | 109 / 502 |
| liver | 89% | 70.42 | 202 / 226 | 21% | 0.52 | 87 / 406 |
| stomach | 75% | 29.45 | 271 / 359 | 35% | 1.11 | 99 / 286 |
| skin | 59% | 19.75 | 1061 / 1809 | 49% | 1.88 | 230 / 472 |
| spleen | 100% | 828.37 | 241 / 241 | 0% | 0 | 0 / 0 |
| bladder | 76% | 41.71 | 16 / 21 | 21% | 0.55 | 107 / 504 |
| adipose | 97% | 73.51 | 1166 / 1204 | 0% | 0 | 0 / 0 |
| ovary | 53% | 21.71 | 95 / 180 | 37% | 1.60 | 161 / 430 |
| lymph node | 0% | 0 | 0 / 0 | 90% | 6.63 | 26 / 29 |
| intestine | 66% | 35.61 | 633 / 966 | 23% | 0.51 | 119 / 527 |
| adrenal gland | 73% | 26.12 | 188 / 258 | 15% | 0.30 | 34 / 230 |
| pancreas | 44% | 15.32 | 143 / 328 | 39% | 0.88 | 69 / 178 |
| peripheral blood | 81% | 882.79 | 754 / 929 | 0% | 0 | 0 / 0 |
| esophagus | 60% | 16.94 | 870 / 1445 | 14% | 0.29 | 26 / 183 |
| blood vessel | 61% | 23.68 | 811 / 1335 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 56% | 1.70 | 25 / 45 |
| heart | 55% | 18.66 | 475 / 861 | 0% | 0 | 0 / 0 |
| brain | 45% | 13.48 | 1193 / 2642 | 8% | 0.15 | 57 / 705 |
| muscle | 26% | 6.66 | 206 / 803 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 8% | 0.23 | 6 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0006955 | Biological process | immune response |
| GO_0007166 | Biological process | cell surface receptor signaling pathway |
| GO_0009897 | Cellular component | external side of plasma membrane |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0004888 | Molecular function | transmembrane signaling receptor activity |
| GO_0019902 | Molecular function | phosphatase binding |
| GO_0005515 | Molecular function | protein binding |
| GO_0042289 | Molecular function | MHC class II protein binding |
| GO_0019903 | Molecular function | protein phosphatase binding |
| Gene name | FCRL6 |
| Protein name | Fc receptor like 6 Fc receptor-like protein 6 (FcR-like protein 6) (FcRL6) (Fc receptor homolog 6) (FcRH6) (IFGP6) |
| Synonyms | FCRH6 |
| Description | FUNCTION: Acts as a MHC class II receptor . When stimulated on its own, does not play a role in cytokine production or the release of cytotoxic granules by NK cells and cytotoxic CD8(+) T cells . Does not act as an Fc receptor . . |
| Accessions | ENST00000368106.4 [Q6DN72-1] ENST00000392235.7 [Q6DN72-4] ENST00000321935.10 [Q6DN72-2] F5GYB3 ENST00000339348.9 [Q6DN72-3] ENST00000536257.5 Q6DN72 |
